Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - OppenheimerSeptember 20, 2016 1:18 PM Sarepta Therapeutic (SRPT) PT Raised to $66 at WedbushSeptember 20, 2016 7:21 AM RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A TargetSeptember 19, 2016 1:52 PM Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon September 19, 2016 1:39 PM